newsfilter
← Earnings
Earnings Releases·

Allogene Therapeutics — Third Quarter 2026 Earnings Summary

Allogene Therapeutics reported a net loss of $50.4 million for the third quarter of 2026, ending the period with $388.9 million in cash, cash equivalents, and investments. The company continues enrollment in the pivotal Phase 2 ALPHA3 trial for cema-cel in first-line large B-cell lymphoma, with completion expected by the end of 2027. Updated clinical data for the Phase 1 RESOLUTION trial of ALLO-329 in autoimmune diseases will be presented at the ACR Convergence in November 2026. Additionally, Allogene appointed Rocio Manghani as Vice President of Market Access, Evidence & Strategy to advance commercial readiness for cema-cel.

Company
ALLOGENE THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology